Recent studies have shown that both HER-2 and HER-3 are overexpressed in liver metastasis CRC patients (8% and 75%, respectively), so they are both promising therapeutic targets for novel treatments [56]. This evidence concerns the gene ERBB2 and colorectal carcinoma.